Citigroup Inc Eagle Pharmaceuticals, Inc. Transaction History

Citigroup Inc

$153 Billion
Q2 2024

A detailed history of Citigroup Inc transactions in Eagle Pharmaceuticals, Inc. stock. As of the latest transaction made, Citigroup Inc holds 1,001,555 shares of EGRX stock, worth $4.29 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,001,555

Previous 2,718 36748.97%

Holding current value

$4.29 Million

Previous $14,000 39957.14%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 12, 2024	BUY	$3.34 - $5.6 $3.34 Million - $5.59 Million	998,837 Added 36748.97%	1,001,555 $5.61 Million
Q1 2024 May 10, 2024	BUY	$4.26 - $6.51 $4,140 - $6,327	972 Added 55.67%	2,718 $14,000
Q4 2023 Feb 09, 2024	BUY	$4.63 - $15.21 $7,144 - $23,469	1,543 Added 760.1%	1,746 $9,000
Q3 2023 Nov 09, 2023	SELL	$15.21 - $22.88 $88,735 - $133,481	-5,834 Reduced 96.64%	203 $3,000
Q2 2023 Aug 10, 2023	SELL	$17.74 - $31.87 $24,392 - $43,821	-1,375 Reduced 18.55%	6,037 $117,000
Q1 2023 May 11, 2023	SELL	$25.06 - $34.09 $660,731 - $898,816	-26,366 Reduced 78.06%	7,412 $210,000
Q4 2022 Feb 09, 2023	SELL	$24.98 - $39.77 $614,832 - $978,859	-24,613 Reduced 42.15%	33,778 $987,000
Q3 2022 Nov 10, 2022	BUY	$26.42 - $47.12 $822,005 - $1.47 Million	31,113 Added 114.06%	58,391 $1.54 Million
Q2 2022 Aug 10, 2022	BUY	$41.26 - $51.35 $460,956 - $573,682	11,172 Added 69.37%	27,278 $1.21 Million
Q1 2022 May 12, 2022	SELL	$44.58 - $52.6 $877,780 - $1.04 Million	-19,690 Reduced 55.01%	16,106 $797,000
Q4 2021 Feb 10, 2022	BUY	$45.82 - $56.9 $666,176 - $827,269	14,539 Added 68.4%	35,796 $1.82 Million
Q3 2021 Nov 10, 2021	BUY	$43.79 - $55.78 $930,844 - $1.19 Million	21,257 New	21,257 $1.19 Million

Others Institutions Holding EGRX

# of Institutions

Shares Held

9.89M

Call Options Held

1.01M

Put Options Held

View Full List

About EAGLE PHARMACEUTICALS, INC.

Ticker EGRX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 13,015,900
Market Cap $55.7M
Description
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and in...

More about EGRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.

Account